The company has not filed an annual or quarterly report since its FY2022 10-K, filed Mar 10, 2023. Its latest SEC filing is a SC 13G/A from Feb 14, 2024.
10-K for FY2022, filed Mar 10, 2023
The sections below describe the company as of the FY2022 annual report.
Develops antibody-based cancer immunotherapies for patients whose tumors have not responded, or may not respond, to existing therapies.
10-K for FY2022, filed Mar 10, 2023
Gilead took a worldwide exclusive license to develop, manufacture and commercialize GS-1811 and related antibodies, and later bought GS-1811.
10-K for FY2022, filed Mar 10, 2023
8-K, filed May 4, 2023
The Offer expired at 6:00 p.m., Eastern Time, on Wednesday, May 3, 2023. According to Computershare Trust Company, N.A., the depositary for…View ↗
A T-cell program moved to Gilead
An antibody program designed to deplete tumor-suppressing T cells was part of Jounce's pipeline in the older report; the latest report says Jounce sold the program to Gilead.
10-K for FY2019, filed Feb 27, 2020 10-K for FY2022, filed Mar 10, 2023JTX-1811 is the most recent product candidate to emerge from our Translational Science Platform. JTX-1811 is a monoclonal antibody designed…View ↗
GS-1811, formerly JTX-1811, which we sold to Gilead Sciences, Inc., or Gilead, in December 2022, was our fourth internally developed…View ↗
Competes with Merck, Immune-Onc Therapeutics, Bristol Myers Squibb, NGM Biopharmaceuticals, Sanofi, Xencor, Agenus, Pfizer, Regeneron Pharmaceuticals, Genentech, AstraZeneca, and GSK
10-K for FY2022, filed Mar 10, 2023traditional cancer therapies, including chemotherapy and targeted therapies; three anti-ILT4 (LILRB2) specific antibody programs in…View ↗
Loading...
